Alzheimer's Drug-Development Program
Funds early drug candidates for Alzheimer's disease, from lab bench through the first human safety trial.
The riskiest, most expensive stretch of drug development sits between finding something promising and watching it survive a first human test, and that stretch is exactly where good Alzheimer's candidates run out of money. This notice funds crossing it.
What it funds is preclinical and early-stage clinical, Phase I, development of novel small-molecule and biologic drug candidates aimed at preventi…
Preclinical through early-stage, Phase I, clinical development of novel small-molecule and biologic drug candidates to prevent, slow the progression of, or treat the cognitive and behavioral symptoms of Alzheimer's disease, run in the investigator's own laboratory or through contract research organizations specializing in preclinical drug development.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up